1.11 USD
+0.28 (+33.73%)
At close: Feb 6, 2026
1.02 USD
-0.09 (-8.11%)
Pre-Market: 2/9/2026, 8:00:13 AM
We assign a fundamental rating of 3 out of 10 to BGMS. BGMS was compared to 523 industry peers in the Biotechnology industry. The financial health of BGMS is average, but there are quite some concerns on its profitability. BGMS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- In the past year BGMS has reported negative net income.
- BGMS had a negative operating cash flow in the past year.
- BGMS had negative earnings in each of the past 5 years.
- BGMS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of BGMS (-85.49%) is worse than 69.98% of its industry peers.
- With a Return On Equity value of -98.28%, BGMS perfoms like the industry average, outperforming 46.85% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.49% | ||
| ROE | -98.28% | ||
| ROIC | N/A |
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Profit Margin and Operating Margin and Gross Margin are not available for BGMS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- BGMS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- BGMS has more shares outstanding than it did 1 year ago.
- The number of shares outstanding for BGMS has been increased compared to 5 years ago.
- BGMS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
- Based on the Altman-Z score of -76.07, we must say that BGMS is in the distress zone and has some risk of bankruptcy.
- With a Altman-Z score value of -76.07, BGMS is not doing good in the industry: 93.12% of the companies in the same industry are doing better.
- There is no outstanding debt for BGMS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -76.07 |
ROIC/WACCN/A
WACC12.44%
2.3 Liquidity
- BGMS has a Current Ratio of 6.43. This indicates that BGMS is financially healthy and has no problem in meeting its short term obligations.
- BGMS's Current ratio of 6.43 is fine compared to the rest of the industry. BGMS outperforms 65.97% of its industry peers.
- A Quick Ratio of 5.07 indicates that BGMS has no problem at all paying its short term obligations.
- The Quick ratio of BGMS (5.07) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.43 | ||
| Quick Ratio | 5.07 |
3. Growth
3.1 Past
- BGMS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.34%, which is quite impressive.
- Looking at the last year, BGMS shows a quite strong growth in Revenue. The Revenue has grown by 9.46% in the last year.
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
3.2 Future
- BGMS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 57.16% yearly.
- BGMS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 1049.89% yearly.
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
- BGMS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BGMS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- BGMS's earnings are expected to grow with 57.16% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.4%
EPS Next 3Y57.16%
5. Dividend
5.1 Amount
- No dividends for BGMS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
1.11
+0.28 (+33.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10
Earnings (Next)03-31 2026-03-31/amc
Inst Owners0.02%
Inst Owner ChangeN/A
Ins Owners62.28%
Ins Owner Change11.22%
Market Cap5.44M
Revenue(TTM)81.00K
Net Income(TTM)-6.97M
Analysts43.33
Price TargetN/A
Short Float %4.48%
Short Ratio1.93
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)58.82%
Min Revenue beat(2)-100%
Max Revenue beat(2)217.65%
Revenue beat(4)1
Avg Revenue beat(4)-20.59%
Min Revenue beat(4)-100%
Max Revenue beat(4)217.65%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 67.15 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.77 | ||
| P/tB | 0.98 | ||
| EV/EBITDA | N/A |
EPS(TTM)-80.13
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-1.24
FCFYN/A
OCF(TTM)-1.24
OCFYN/A
SpS0.02
BVpS1.45
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -85.49% | ||
| ROE | -98.28% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-203.37%
ROA(5y)-137.74%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 6.43 | ||
| Quick Ratio | 5.07 | ||
| Altman-Z | -76.07 |
F-Score5
WACC12.44%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.97%
EPS Next Y39.49%
EPS Next 2Y19.4%
EPS Next 3Y57.16%
EPS Next 5YN/A
Revenue 1Y (TTM)9.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%710%
Revenue Next Year88.68%
Revenue Next 2Y37.36%
Revenue Next 3Y1049.89%
Revenue Next 5YN/A
EBIT growth 1Y40.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y64.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.9%
OCF growth 3YN/A
OCF growth 5YN/A
BIO GREEN MED SOLUTION INC / BGMS FAQ
What is the ChartMill fundamental rating of BIO GREEN MED SOLUTION INC (BGMS) stock?
ChartMill assigns a fundamental rating of 3 / 10 to BGMS.
Can you provide the valuation status for BIO GREEN MED SOLUTION INC?
ChartMill assigns a valuation rating of 1 / 10 to BIO GREEN MED SOLUTION INC (BGMS). This can be considered as Overvalued.
How profitable is BIO GREEN MED SOLUTION INC (BGMS) stock?
BIO GREEN MED SOLUTION INC (BGMS) has a profitability rating of 0 / 10.
How financially healthy is BIO GREEN MED SOLUTION INC?
The financial health rating of BIO GREEN MED SOLUTION INC (BGMS) is 6 / 10.